{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:44:58Z","timestamp":1772689498983,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Key R & D Program of China","award":["2016YFD0500800"],"award-info":[{"award-number":["2016YFD0500800"]}]},{"name":"National Key R & D Program of China","award":["2016YFD0500809"],"award-info":[{"award-number":["2016YFD0500809"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["21821005"],"award-info":[{"award-number":["21821005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["81773623"],"award-info":[{"award-number":["81773623"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["21808226"],"award-info":[{"award-number":["21808226"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.vaccine.2018.12.073","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:21:20Z","timestamp":1547511680000},"page":"956-964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein"],"prefix":"10.1016","volume":"37","author":[{"given":"Lingling","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5793-5286","authenticated-orcid":false,"given":"Songping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2018.12.073_b0005","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.12.073_b0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40121-016-0107-0","article-title":"Meningococcal vaccinations","volume":"5","author":"Crum-CianfloneN","year":"2016","journal-title":"Infect Dis Ther"},{"issue":"9580","key":"10.1016\/j.vaccine.2018.12.073_b0015","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2018.12.073_b0020","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/nm.2535","article-title":"A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design","volume":"17","author":"Avci","year":"2011","journal-title":"Nat Med"},{"issue":"4426","key":"10.1016\/j.vaccine.2018.12.073_b0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/174405a0","article-title":"Detoxification of diphtheria toxin with formaldehyde mixed with an amino-acid","volume":"174","author":"Neum\u00fcller","year":"1954","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2018.12.073_b0030","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/nar\/12.10.4063","article-title":"The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197","volume":"12","author":"Giannini","year":"1984","journal-title":"Nucl Acids Res"},{"issue":"9","key":"10.1016\/j.vaccine.2018.12.073_b0035","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.4049\/jimmunol.145.9.3071","article-title":"Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine","volume":"145","author":"Donnelly","year":"1990","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2018.12.073_b0040","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/erv.09.113","article-title":"10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix","volume":"8","author":"Prymula","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"13","key":"10.1016\/j.vaccine.2018.12.073_b0045","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.vaccine.2014.01.047","article-title":"Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines","volume":"32","author":"Pobre","year":"2014","journal-title":"Vaccine"},{"issue":"34","key":"10.1016\/j.vaccine.2018.12.073_b0050","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: a review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.12.073_b0055","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/IAI.66.5.2093-2098.1998","article-title":"Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants","volume":"66","author":"Dagan","year":"1998","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2018.12.073_b0060","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/eji.200425755","article-title":"Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles","volume":"35","author":"Schwarz","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2018.12.073_b0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin Immunol"},{"issue":"40","key":"10.1016\/j.vaccine.2018.12.073_b0070","doi-asserted-by":"crossref","first-page":"12360","DOI":"10.1073\/pnas.1510533112","article-title":"Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery","volume":"112","author":"Lu","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2018.12.073_b0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1586\/erv.12.150","article-title":"Hepatitis B core-based virus-like particles to present heterologous epitopes","volume":"12","author":"Roose","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2018.12.073_b0080","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000050037","article-title":"HBV core particles as a carrier for B cell\/T cell epitopes","volume":"44","author":"Pumpens","year":"2001","journal-title":"Intervirology"},{"issue":"4","key":"10.1016\/j.vaccine.2018.12.073_b0085","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1134\/S0026893316040099","article-title":"The true story and advantages of the famous Hepatitis B virus core particles: outlook 2016","volume":"50","author":"Pumpens","year":"2016","journal-title":"Mol Biol"},{"issue":"6146","key":"10.1016\/j.vaccine.2018.12.073_b0090","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/330381a0","article-title":"Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein","volume":"330","author":"Clarke","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.12.073_b0095","first-page":"2417","article-title":"Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model","volume":"11","author":"Chu","year":"2016","journal-title":"Int J Nanomed"},{"issue":"29","key":"10.1016\/j.vaccine.2018.12.073_b0100","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1016\/j.vaccine.2015.04.073","article-title":"Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e","volume":"33","author":"Tsybalova","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.12.073_b0105","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-3083.2007.01900.x","article-title":"Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus","volume":"65","author":"Zhang","year":"2007","journal-title":"Scand J Immunol"},{"issue":"43","key":"10.1016\/j.vaccine.2018.12.073_b0110","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1016\/j.vaccine.2015.09.021","article-title":"Molecular shape and immunogenicity of meningococcal polysaccharide group A conjugate vaccine","volume":"33","author":"Xu","year":"2015","journal-title":"Vaccine"},{"issue":"S2","key":"10.1016\/j.vaccine.2018.12.073_b0115","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.12.073_b0120","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jconrel.2013.03.008","article-title":"PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine","volume":"172","author":"Huang","year":"2013","journal-title":"J Control Release"},{"issue":"9","key":"10.1016\/j.vaccine.2018.12.073_b0125","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.vaccine.2015.01.031","article-title":"Size-exclusion HPLC provides a simple, rapid, and versatile alternative method for quality control of vaccines by characterizing the assembly of antigens","volume":"33","author":"Yang","year":"2015","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.12.073_b0130","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/0006-3002(57)90254-8","article-title":"Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method","volume":"24","author":"Svennerholm","year":"1957","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/j.vaccine.2018.12.073_b0135","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0731-7085(99)00183-1","article-title":"Quantitation of low level unconjugated polysaccharide in tetanus toxoid-conjugate vaccine by HPAEC\/PAD following rapid separation by deoxycholate\/HCl","volume":"21","author":"Lei","year":"2000","journal-title":"J Pharmaceut Biomed"},{"issue":"1","key":"10.1016\/j.vaccine.2018.12.073_b0140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/03079458908418589","article-title":"Quantitative estimation of Newcastle disease virus antibody levels in chickens and turkeys by ELISA","volume":"18","author":"Adair","year":"1989","journal-title":"Avian Pathol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.12.073_b0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0022-1759(88)90196-2","article-title":"The measurement of relative antibody affinity by ELISA using thiocyanate elution","volume":"106","author":"Macdonald","year":"1988","journal-title":"J Immunol Methods"},{"issue":"41","key":"10.1016\/j.vaccine.2018.12.073_b0150","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1016\/j.vaccine.2007.07.037","article-title":"Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid","volume":"25","author":"Silveira","year":"2007","journal-title":"Vaccine"},{"issue":"Pt3","key":"10.1016\/j.vaccine.2018.12.073_b0155","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/BA20020066","article-title":"Evaluation of meningococcal C oligosaccharide conjugate vaccines by size-exclusion chromatography\/multi-angle laser light scattering","volume":"36","author":"Jumel","year":"2002","journal-title":"Biotechnol Appl Biochem"},{"issue":"2","key":"10.1016\/j.vaccine.2018.12.073_b0160","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1128\/IAI.41.2.609-617.1983","article-title":"Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice","volume":"41","author":"Beuvery","year":"1983","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2018.12.073_b0165","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.vaccine.2005.05.041","article-title":"Relationships among physico-chemical and biological tests for a synthetic Hib-TT conjugate vaccine","volume":"25","author":"Cuervo","year":"2007","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.vaccine.2018.12.073_b0170","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1016\/j.vaccine.2015.04.094","article-title":"Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine","volume":"33","author":"Zhang","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.073_b0175","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejpb.2016.07.004","article-title":"The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine","volume":"107","author":"Donadei","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"issue":"10","key":"10.1016\/j.vaccine.2018.12.073_b0180","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1586\/erv.09.81","article-title":"Virus-like particle vaccines and adjuvants: the HPV paradigm","volume":"8","author":"Buonaguro","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2018.12.073_b0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1099\/vir.0.80580-0","article-title":"The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate","volume":"86","author":"Vanlandschoot","year":"2005","journal-title":"J Gen Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19300544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19300544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:38:28Z","timestamp":1694558308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19300544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0264410X19300544"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}